Prognostic significance of the immunohistochemical expression of O 6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas: Original Article

Neuropathology

Volumn 29, Issue 4, 2009, Pages 379-388

  Nakagawa, Takao ^a   Ido, Kazunori ^a   Sakuma, Takahiro ^a   Takeuchi, Hiroaki ^a   Sato, Kazufumi ^a   Kubota, Toshihiko ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Glioblastoma; Immunohistochemistry; MRP 1; O6 MGMT; P glycoprotein; Prognosis

Indexed keywords

BETA INTERFERON; CARBOPLATIN; ETOPOSIDE; GLYCOPROTEIN P; HUMAN INTERFERON; HUMAN INTERFERON BETA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; NIMUSTINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67651246847     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2008.00983.x     Document Type: Article

References (18)

1. Mineo JF, Bordron A, Baroncini M et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 2007 149 : 245 253.
2. Belanich M, Pastor M, Randall T et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996 56 : 783 788.
3. Anda T, Shabani HK, Tsunoda K et al. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 2003 25 : 241 248.
4. Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 10 : 1871 1874.
5. Blanc JL, Wager M, Guilhot J et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004 68 : 275 283.
6. Kamiryo T, Tada K, Shiraishi S et al. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2- chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004 54 : 349 357.
7. Watanabe T, Katayama Y, Komine C et al. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005 113 : 581 587.
8. Crinière E, Kaloshi G, Laigle-Donadey F et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007 83 : 173 179.
9. Nakagawa T, Kubota T, Ido K et al. The combined effects of multiple chemotherapeutic agents for malignant glioma cells. J Neurooncol 2007 84 : 31 37.
10. Nakasu S, Fukami T, Baba K et al. Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 2004 70 : 333 340.
11. Reavey-Cantwell JF, Haroun RI, Zahurak M et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 2001 55 : 195 204.
12. Esteller M, Hamilton SR, Burger PC et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999 59 : 793 797.
13. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 352 : 987 996.
14. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol 2002 3 : 397 406.
15. Brell M, Tortosa A, Verger E et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005 11 : 5167 5174.
16. Ogino S, Kawasaki T, Brahmandam M et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006 8 : 209 217.
17. Cankovic M, Mikkelsen T, Rosenblum ML et al. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007 87 : 392 397.
18. Andersson U, Malmer B, Bergenheim AT et al. Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 2004 23 : 21 27.